CSIMarket
 


Pfenex Inc   (PFNX)
Other Ticker:  
 

Pfenex Inc 's Leverage Ratio

PFNX's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 42.05%, Leverage Ratio fell to 0.12, below the Pfenex Inc 's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the second quarter 2020, 98 other companies have achieved lower Leverage Ratio than Pfenex Inc in the II Quarter 2020. While Leverage Ratio total ranking has deteriorated compared to the first quarter 2020 from 34 to 276 .

Explain Leverage Ratio?
Who are PFNX Customers?
What are PFNX´s Total Liabilities?


PFNX Leverage Ratio (Jun 30 2020)
II. Quarter
(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
Y / Y Equity Change 42.62 % 42.25 % 18.26 % -17.06 % -32.76 %
Y / Y Total Liabilities Change -30.54 % -56 % -56.6 % -39.17 % -49.19 %
Leverage Ratio MRQ 0.12 0.07 0.12 0.24 0.24
PFNX's Total Ranking # 276 # 34 # 159 # 197 # 413
Seq. Equity Change -11.16 % 15.04 % 29.49 % 7.76 % -11.39 %
Seq. Total Liabilities Change 42.05 % -31.14 % -35.19 % 9.57 % -10 %



Leverage Ratio second quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 99
Healthcare Sector # 149
Overall Market # 276


Leverage Ratio Statistics
High Average Low
1.16 0.43 0.07
(Mar 31 2015)   (Mar 31 2020)




Financial Statements
Pfenex Inc 's Equity $ 74 Millions Visit PFNX's Balance sheet
Pfenex Inc 's Total Liabilities $ 9 Millions Visit PFNX's Balance sheet
Source of PFNX's Sales Visit PFNX's Sales by Geography


Cumulative Pfenex Inc 's Leverage Ratio

PFNX's Leverage Ratio for the trailling 12 Months

PFNX Leverage Ratio

(Jun 30 2020)
II. Quarter
(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
Y / Y Equity TTM Growth 42.62 % 42.25 % 18.26 % -17.06 % -32.76 %
Y / Y Total Liabilities TTM Growth -30.54 % -56 % -56.6 % -39.17 % -49.19 %
Leverage Ratio TTM 0.13 0.15 0.2 0.26 0.29
Total Ranking TTM # 11 # 277 # 297 # 490 # 10
Seq. Equity TTM Growth -11.16 % 15.04 % 29.49 % 7.76 % -11.39 %
Seq. Total Liabilities TTM Growth 42.05 % -31.14 % -35.19 % 9.57 % -10 %


On the trailing twelve months basis Despite of the net new borrowings of 42.05% during the twelve months period ending in II Quarter 2020 Pfenex Inc has managed to decrease Leverage Ratio in the II Quarter 2020 to 0.13, below Pfenex Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry PFNX recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has improved so far to 11, from total ranking in previous 12 month period at 277.

Explain Leverage Ratio?
Who are PFNX Customers?
What are PFNX´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 0
Healthcare Sector # 0
Within the Market # 11


trailing twelve months Leverage Ratio Statistics
High Average Low
2.73 0.56 0.17
(Mar 31 2015)   (Jun 30 2020)




Companies with similar Leverage Ratio in the quarter ending Jun 30 2020, within Major Pharmaceutical Preparations Industry Leverage RatioJun 30 2020 MRQ Total LiabilitiesJun 30 2020 MRQ Equity
Intec Pharma Ltd   0.31 $ 5.069  Millions$ 16.178  Millions
Cormedix Inc   0.31 $ 5.716  Millions$ 18.521  Millions
Kadmon holdings inc   0.31 $ 49.987  Millions$ 163.257  Millions
Syndax Pharmaceuticals Inc   0.30 $ 44.981  Millions$ 147.647  Millions
Hepion Pharmaceuticals inc   0.30 $ 5.517  Millions$ 18.292  Millions
Eyenovia inc   0.29 $ 2.427  Millions$ 8.319  Millions
Avenue Therapeutics Inc   0.29 $ 1.193  Millions$ 4.101  Millions
Chemocentryx Inc.  0.29 $ 120.903  Millions$ 421.141  Millions
Siga Technologies Inc  0.28 $ 26.284  Millions$ 94.133  Millions
Agile Therapeutics Inc  0.27 $ 22.186  Millions$ 80.796  Millions
Vbi Vaccines Inc  0.27 $ 34.574  Millions$ 126.613  Millions
Advaxis Inc   0.27 $ 8.553  Millions$ 31.466  Millions
Nektar Therapeutics  0.27 $ 338.638  Millions$ 1,256.240  Millions
Frequency Therapeutics Inc   0.27 $ 43.085  Millions$ 161.701  Millions
Cue Biopharma Inc   0.26 $ 21.199  Millions$ 80.154  Millions
Corvus Pharmaceuticals Inc   0.26 $ 13.337  Millions$ 50.840  Millions
Spero Therapeutics Inc   0.26 $ 19.208  Millions$ 73.714  Millions
Neurobo Pharmaceuticals Inc   0.26 $ 3.214  Millions$ 12.338  Millions
Odonate Therapeutics Inc   0.26 $ 27.179  Millions$ 105.548  Millions
Scpharmaceuticals Inc   0.25 $ 24.708  Millions$ 98.059  Millions
Vascular Biogenics Ltd   0.25 $ 7.582  Millions$ 30.917  Millions
G1 Therapeutics Inc   0.24 $ 49.752  Millions$ 203.845  Millions
Xenetic Biosciences Inc   0.24 $ 3.706  Millions$ 15.358  Millions
Axsome Therapeutics Inc   0.24 $ 36.746  Millions$ 154.243  Millions
Altimmune Inc   0.24 $ 18.932  Millions$ 79.522  Millions
Zymeworks Inc   0.24 $ 115.600  Millions$ 491.253  Millions
Hookipa Pharma inc   0.23 $ 24.195  Millions$ 103.915  Millions
Amarin Corp Plcuk  0.23 $ 137.851  Millions$ 602.763  Millions
Lftd Partners Inc   0.22 $ 4.734  Millions$ 21.115  Millions
Nighthawk Biosciences inc   0.22 $ 10.440  Millions$ 47.136  Millions

Date modified: 2023-03-25T02:50:16+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com